PD-L1 Expression in Triple-Negative Breast Cancer

Elizabeth A. Mittendorf1, Anne V. Philips1, Funda Meric-Bernstam1, Na Qiao1, Yun Wu2, Susan Harrington3, Xiaoping Su3, Ying Wang3, Ana M. Gonzalez-Angulo1, Argun Akcakanat1, Akhil Chawla1, Michael Curran5, Patrick Hwu6, Padmanee Sharma7, Jennifer K. Litton4, Jeffrey J. Molldrem8, and Gheath Alatrash8

Abstract

Early-phase trials targeting the T-cell inhibitory molecule programmed death ligand 1 (PD-L1) have shown clinical efficacy in cancer. This study was undertaken to determine whether PD-L1 is overexpressed in triple-negative breast cancer (TNBC) and to investigate the loss of PTEN as a mechanism of PD-L1 regulation. The Cancer Genome Atlas (TCGA) RNA sequencing data showed significantly greater expression of the PD-L1 gene in TNBC (n = 120) compared with non-TNBC (n = 716; P < 0.001). Breast tumor tissue microarrays were evaluated for PD-L1 expression, which was present in 19% (20 of 105) of TNBC specimens. PD-L1+ tumors had greater CD8+ T-cell infiltrate than PD-L1– tumors (688 cells/mm vs. 263 cells/mm; P < 0.0001). To determine the effect of PTEN loss on PD-L1 expression, stable cell lines were generated using PTEN short hairpin RNA (shRNA). PTEN knockdown led to significantly higher cell-surface PD-L1 expression and PD-L1 transcripts, suggesting transcriptional regulation. Moreover, phosphoinositide 3-kinase (PI3K) pathway inhibition using the AKT inhibitor MK-2206 or rapamycin resulted in decreased PD-L1 expression, further linking PTEN and PI3K signaling to PD-L1 regulation. Coculture experiments were performed to determine the functional effect of altered PD-L1 expression. Increased PD-L1 cell surface expression by tumor cells induced by PTEN loss led to decreased T-cell proliferation and increased apoptosis. PD-L1 is expressed in 20% of TNBCs, suggesting PD-L1 as a therapeutic target in TNBCs. Because PTEN loss is one mechanism regulating PD-L1 expression, agents targeting the PI3K pathway may increase the antitumor adaptive immune responses. Cancer Immunol Res; 2(4); 361–70. ©2014 AACR.

Introduction

Triple-negative breast cancer (TNBC), which constitutes 10% to 20% of all breast tumors, is characterized by a lack of expression of estrogen receptor (ER), progesterone receptor (PR), and HER2/neu (HER2; refs. 1, 2). TNBCs are generally high-grade, aggressive tumors with a high rate of distant metastasis and poorer disease-specific survival than other breast cancer subtypes (1, 3). The poor outcomes occur even though standard chemotherapy regimens have activity against these tumors. Studies evaluating chemotherapy in the neoadjuvant setting have demonstrated that TNBC has higher rates of pathologic complete response than other tumor types; however, there is a paradoxical shortening of progression-free and overall survival (4). Therefore, novel therapeutic strategies are needed to improve the management of patients with TNBC.

There is significant heterogeneity within TNBC. A study analyzing gene expression profiles identified six TNBC subtypes, one of which was an immunomodulatory subtype enriched for genes involved in immune cell processes including immune cell signaling, cytokine signaling, antigen processing and presentation, and signaling through core immune signal transduction pathways (2). In a meta-analysis incorporating published gene expression data with clinicopathologic data, investigators developed gene expression modules related to key biologic processes in breast cancer. For TNBC, only the immune response module was associated with clinical outcome (5). Loi and colleagues recently reported a prognostic role of tumor-infiltrating lymphocytes (TIL) in TNBC in a large prospective clinical trial (6), and in a study looking specifically at CD8+ intratumoral lymphocytes, Liu and colleagues found that TNBC had higher rates of CD8+ T-cell infiltration, which was an independent favorable prognostic factor (7). Taken together, these data suggest that immunotherapy may have a role in the management of patients with TNBC.

A promising approach to augmenting antitumor immunity is blockade of immune checkpoints. One example is CTLA-associated antigen 4 (CTLA-4), a T-cell inhibitory receptor that is expressed on activated CD8+ T cells. CTLA-4 attenuates the T-cell immune response by counteracting the activity of the T-cell costimulatory receptor CD28 (8, 9). Ipilimumab, a monoclonal antibody targeting CTLA-4, has received approval from the U.S. Food and Drug Administration for...
the treatment of metastatic or unresectable melanoma. Programmed cell death protein 1 (PD-1) is a second immune checkpoint receptor that limits T-cell effector function within tissues (10). PD-1 has two known ligands, PD-L1 and PD-L2, which have distinct expression profiles with PD-L1 being expressed on several tumor types (11). In a small study of 44 breast tumors, PD-L1 was shown to be expressed in 34% of the tumors and the expression was associated with high-risk clinicopathologic features, including high histologic grade and hormone receptor-negative status (12). Recently reported phase I studies evaluating antibodies targeting either PD-1 or PD-L1 have shown that these agents elicited durable, objective responses in patients with melanoma, non-small-cell lung cancer, and renal-cell carcinoma (13, 14).

PD-L1 regulation is an area of active investigation. One mechanism of regulation is the induction of tumor cell surface expression of PD-L1 in response to IFN-γ (11). This is likely a mechanism whereby tumor cells evade the antitumor immune response of tumor-specific T cells. A second mechanism is through oncogenic signaling. Expression of PD-L1 on glioblastomas is increased by the deletion or silencing of PTEN, implicating involvement of the phosphoinositide 3-kinase (PI3K) pathway (15). The PTEN/PI3K pathway is important in breast cancer as PD-L1 loss and phosphatidylinositol-4,5-bisphosphate 3-kinase (PIK3CA) mutations have been identified in approximately 30% and 40% of primary breast tumors, respectively (16). Furthermore, PTEN loss is correlated with ER/PR-negative tumors (17). Recently published data from The Cancer Genome Atlas (TCGA) showed that basal-like tumors, the majority of which were TNBCs, showed PTEN mutation or loss in 35% of tumors, which also correlated with PI3K pathway activation (18).

In this study, we hypothesized that TNBCs express PD-L1 and that PD-L1 expression may be regulated in part by PTEN loss. We show that 20% of TNBCs express PD-L1 and PTEN is deficient in almost half of the PD-L1-expressing tumors. Furthermore, we show that PTEN knockdown results in increased cell surface PD-L1 expression, an effect that is in part transcriptionally regulated. Increased PD-L1 expression following PTEN knockdown has functional consequences, as we show that activated T cells cocultured with PTEN-silenced breast cancer cells have decreased proliferation and increased apoptosis. Taken together, these data provide evidence for PTEN loss as a mechanism regulating PD-L1 expression in TNBC and suggest that antibodies targeting PD-1 or PD-L1 may have utility as a novel therapeutic strategy in TNBC.

Materials and Methods

Study patients, tumors and cell lines

TCGA RNA sequencing data were obtained from the Cancer Genomics Hub (CGHub; https://cghub.ucsc.edu) and the TCGA Data Portal (https://tcga-data.nci.nih.gov/tcga/). Tumor samples used to construct tissue microarrays (TMA) and peripheral blood mononuclear cells (PBMC) were obtained through an Institutional Review Board-approved protocol. Tumors were considered hormone receptor-negative if nuclear staining for both the ERs and PRs was ≤ 5%. Tumors were considered HER2-negative if they were 0 or 1+ by immunohistochemistry (IHC) or 2+ by IHC and negative for gene amplification by FISH. Fresh-frozen tumor samples used to isolate breast cancer cells by laser capture microdissection (LCM) were obtained from Origene. Cultured breast cancer cell lines were obtained from American Type Culture Collection. Cell lines were validated by short tandem repeat (STR) DNA fingerprinting using the AmpF/STR Identifier Kit according to the manufacturer’s instructions (Applied Biosystems). Cells were cultured in Dulbecco’s Modified Eagle Medium with 10% FBS, 100 U/mL penicillin, and 100 μg/mL streptomycin.

Immunohistochemistry

One-millimeter cores from paraffin blocks of breast tumors were used to generate TMAs. Before staining, microarrays were baked overnight after which they were deparaffinized and rehydrated. Nonspecific binding was blocked and then the sections were incubated with primary antibody. For PD-L1 staining, the primary antibody used was 5H1, a mouse anti-human PD-L1 monoclonal antibody previously reported by Dong and colleagues for human tumor staining (19, 20). The specificity of this antibody for PD-L1 was validated using a PD-L1 fusion protein and PD-L1–transduced melanoma cells (positive control) and nontransduced parental cells (negative control; ref. 20). Slides were stained for 60 minutes with antibody diluted at 1:300 with antibody diluent containing background-reducing components. Slides were washed and incubated in fluorescein isothiocyanate (FITC)-labeled antimouse immunoglobulins and then anti-FITC horseradish peroxidase (HRP). Slides were visualized with 3,3′-diaminobenzidine (DAB). Consistent with the previous reports of PD-L1 staining using the 5H1 antibody in renal cell carcinoma, cell surface membrane staining >5% was considered positive (20). For PD-L1 staining, TMAs were incubated with primary anti-PTEN antibody (1:100; clone 6H2.1; Dako). After washing, slides were incubated with the secondary anti-mouse immunoglobulin G (IgG) conjugated with HRP, and then visualized with chromogen DAB. Any staining of PTEN was considered positive. For CD8 staining, TMAs were incubated with primary anti-CD8 antibody (1:20; LabVision). Slides were incubated with the secondary anti-mouse IgG-biotin antibody (1:200; Vectastain Elite ABC Kit; Vector Laboratories), and then with the avidin–biotin peroxidase complex (1:100; Vectastain Elite ABC Kit), after which visualization was conducted with chromagen. The number of CD8+ T cells per 1-mm core was determined. Human tonsil tissue was used as a positive control for both PD-L1 and CD8 staining. For PD-L1 staining, irrelevant isotype-matched antibodies were used to control for nonspecific staining during protocol development. Specificity of staining was confirmed by preincubation of primary antibody with recombinant PD-L1 antibody. For CD8 staining, omission of primary antibodies was used as a negative staining control.

RNA extraction and amplification, cDNA synthesis, and reverse transcription PCR

Breast cancer cells were isolated from fresh-frozen tumor samples by LCM and RNA was extracted, purified, and amplified as described previously (21). Before PCR, RNA was amplified using the Arcturus Ribonuclease A Amplification Kit (Life
Technologies, Applied Biosystems) to generate amplified anti-sense RNA (aRNA), cDNA was synthesized from 1 µg of aRNA using the Roche Transcriptor First Strand cDNA Synthesis Kit (Roche Applied Science). For cultured cell lines, total cellular RNA was extracted using the RNeasy Mini Kit (Qiagen). cDNA was synthesized from 2 µg of RNA using the Roche Transcriptor First Strand cDNA Synthesis Kit. Reverse transcription PCR (RT-PCR) reactions were performed on an iCycler iQ thermal cycler (Bio-Rad Laboratories). Quantitative RT-PCR (qRT-PCR) was performed on a StepOnePlus instrument (Applied Biosystems). Data were analyzed as relative mRNA expression quantified with StepOnePlus software and normalized to actin transcription levels. Primer sequences used included: cytokeratin 7 (CK7; forward primer 5’-TGTGGATCCTAGAATTACCAAG-3’, reverse primer 5’-TCCTGTCAGCATC-3’), PD-L1 (forward primer 5’-GATATTGCGGAGGATCGGCA-3’, reverse primer 5’-TGTCGATGCTGCCTACATGA-3’), PTEN (forward primer 5’-AGCACCACAGATGTGTCGGAGA-3’, reverse primer 5’-TCCTGTCAGCATC-3’), and actin, an endogenous control, (forward primer 5’-GAAACATTGTGCGGACGAT-3’, reverse primer 5’-GAAACATTGTGCGGACGAT-3’: oligonucleotides from Sigma-Aldrich).

**shRNA constructs and transduction**

PTEN short hairpin RNA (shRNA) lentiviral transduction particles (TRCN0000002746 and TRCN0000002749) and non-targeting shRNA lentiviral transduction particles [pLKO.1-puro Non-Target Control (SHC016V)] were obtained from Sigma-Aldrich. Transductions were performed with 1 x 10⁴ cells per well in 96-well plates. Lentiviral particles were added at a multiplicity of infection of 5. After 48 hours, media was changed to fresh media with 2 µg/mL puromycin. Media was replaced every third day with fresh puromycin-containing media until stable clones were identified. PTEN knockdown was confirmed using Western blot analysis.

**Drug reagents**

MK-2206 was provided (to F. Meric-Bernstam) by the SU2C PI3K Dream Team Consortium. Rapamycin was purchased from LC Laboratories, Inc.

**Flow cytometry analysis**

To assess cell PD-L1 expression, cells were stained with phycoerythrin (PE)-conjugated anti-PD-L1 antibody (eBioscience). Aqua LIVE/DEAD stain (Invitrogen) was used to assess cell viability. Flow cytometry was performed using the Fortessa flow cytometer (BD Biosciences) and data were analyzed using FlowJo software (TreeStar Inc.).

**T-cell proliferation assay**

CD4⁺ and CD8⁺ T cells were isolated from healthy donor PBMC using negative selection kits (Miltenyi Biotech). Cells were labeled with carboxyfluorescein succinimidyl ester (CFSE; Invitrogen) after which 3 x 10⁶ CD4⁺ or CD8⁺ T cells were combined with 1 x 10⁴ to 1 x 10⁵ breast cancer cells and seeded into 96-well plates. T cells were stimulated by the addition of anti-CD3 and anti-CD28 antibodies (3 µg/mL; BD Biosciences). After 72 hours, cells were stained with aliphycocyanin (APC)-conjugated anti-CD4 antibody, PE-conjugated anti-CD8 antibody and Aqua LIVE/DEAD stain (BD Biosciences). Flow cytometry analyses were performed as described above.

**Apoptosis assay**

CD4⁺ or CD8⁺ T cells were isolated from PBMCs and were plated with breast cancer cells at a 1:1 ratio (3 x 10⁶) in 96-well plates. T cells were stimulated with anti-CD3 and anti-CD28 antibodies. Cells were cocultured at 37°C for 20 hours after which they were stained with APC-conjugated anti-CD4 antibody and PE-conjugated anti-CD8 antibody. Cells were washed in PBS and then resuspended in Annexin binding buffer containing FITC-conjugated Annexin V and 7-amino-actinomycin D (7-AAD) viability stain (BD Biosciences). Flow cytometry analyses were performed as described above.

**Statistical analysis**

Comparison of PD-L1 between TNBC and non-TNBC samples in the TCGA dataset was made using a two-sample t test performed in R (http://www.R-project.org). Remaining statistical analyses were performed using GraphPad Prism 5.0 software. P < 0.05 were considered significant.

**Results**

**TNB expresses PD-L1**

To evaluate the presence of PD-L1 in breast cancer, we used the TCGA RNA sequencing data to determine whether the PD-L1 transcript was present. This analysis demonstrated differential PD-L1 expression with significantly higher levels in TNBC (n = 120) as compared with non-TNBC (n = 716) samples (P < 0.001; Fig. 1A). Because whole tumors such as those evaluated by TCGA contain cells of the microenvironment including inflammatory cells that might express PD-L1, we next performed LCM to isolate breast cancer cells from primary tumors. Following RNA extraction, qRT-PCR confirmed the presence of PD-L1 mRNA in all five samples with transcript levels in three tumors being higher than in the MDA-MB-231 cell line, which has been shown to have baseline high PD-L1 expression (Fig. 1B; ref. 12). Two of the three tumors (LCM1 and LCM 4) with the highest PD-L1 mRNA levels were TNBCs.

Having shown the presence of PD-L1 transcripts in breast tumors, we next evaluated PD-L1 expression at the protein level. Immunohistochemical staining for PD-L1 expression was performed on a TMA comprising 105 tumors from patients with early-stage TNBC who had not received neoadjuvant chemotherapy. PD-L1 expression, defined as ≥5% membranous staining, was identified in 20 (19%) of the tumors. Furthermore, nine of 17 evaluable PD-L1⁺ tumors were negative for PTEN staining on IHC. Staining for the presence of CD8⁺ T cells was available for 82 tumors. For tumors that were PD-L1⁺, the average number of CD8⁺ T cells per 1-mm core was 668, compared with 263 for tumors that were PD-L1⁻ (P < 0.0001; Fig. 1C and D).

Taken together, these data confirm that TNBC expresses PD-L1, and approximately half of the PD-L1⁺ tumors did not express PTEN.

**PD-L1 expression and PTEN status**

Having demonstrated PD-L1 expression in approximately 20% of TNBC specimens, we next screened a panel of cell lines,
including five TNBC cell lines, for cell surface PD-L1 expression (Fig. 2). Four of the five TNBC cell lines expressed high levels of cell-surface PD-L1; two of these PD-L1–expressing TNBC cell lines (MDA-MB-468 and BT-549) are PTEN deficient (22). Notably, the TNBC cell line MDA-MB-157, which has wild-type PTEN, had low levels of PD-L1 expression. Our data also show PTEN expression in the MDA-MB-231 and HS-578 TNBC cell lines, which have high levels of cell surface PD-L1, suggesting that there are other mechanisms of PD-L1 regulation in addition to PTEN.

We next sought to further investigate if PTEN regulates PD-L1 expression. We transduced the MDA-MB-157 cell line, which expresses PTEN and low levels of cell surface PD-L1, with two different PTEN lentiviral shRNA vectors to generate stable PTEN knockdown clones (Fig. 3A). Cell surface PD-L1 expression was assessed using flow cytometry. As shown (Fig. 3D), loss of PTEN led to a significant increase in PD-L1 cell surface expression \((P < 0.0001)\). Results were confirmed in the MCF-7 cell line (Fig. 3B and E), which also expresses PTEN and low levels of cell surface PD-L1. In addition, we showed that PTEN knockdown in the MDA-MB-231 cell line resulted in a greater increase in PD-L1 expression than the addition of IFN-\(\gamma\), which is known to enhance PD-L1 expression (Supplementary Fig. 1).

For all three cell lines, RNA was extracted and qRT-PCR analysis was done using a \(t\) test. Log2 expression of PD-L1 is shown on the \(y\)-axis. B, PD-L1 mRNA expression (mean \(\pm\) SD) in breast cancer patient tumors was measured using RT-PCR. RNA was extracted from breast cancer cells that were isolated from tumors using LCM (1–5). Cytokeratin 7 (CK7) was used as a marker of breast cancer to confirm the source of the extracted RNA. MDA-MB-231 was used as a positive control for PD-L1. C, representative TNBC patient tumor tissues showing loss of PTEN expression and high PD-L1 expression in tumor cells, and a significant CD8\(^+\) T-cell infiltrate in contrast with another TNBC patient tissue (D), which shows high PTEN expression in breast tumor cells, no PD-L1 expression in tumor cells, minimal PD-L1 expression in associated inflammatory cells, and minimal intratumoral CD8\(^+\) T-cell infiltrate. Magnification, \(\times\) 100. H&E, hematoxylin and eosin.

**Effects of inhibiting the PI3K pathway on PD-L1 expression**

Cancer cells lacking PTEN have increased levels of PI3K activity. To determine whether PTEN regulation of PD-L1 in TNBC is mediated by PI3K signaling, we treated MDA-MB-468 cells with either the Akt inhibitor MK-2206 or the mTOR inhibitor rapamycin. MDA-MB-468 was chosen because it has minimal PD-L1 expression (mean \(\pm\) SD) in breast cancer patient tumors was measured using RT-PCR. RNA was extracted from breast cancer cells that were isolated from tumors using LCM (1–5). Cytokeratin 7 (CK7) was used as a marker of breast cancer to confirm the source of the extracted RNA. MDA-MB-231 was used as a positive control for PD-L1. C, representative TNBC patient tumor tissues showing loss of PTEN expression and high PD-L1 expression in tumor cells, and a significant CD8\(^+\) T-cell infiltrate in contrast with another TNBC patient tissue (D), which shows high PTEN expression in breast tumor cells, no PD-L1 expression in tumor cells, minimal PD-L1 expression in associated inflammatory cells, and minimal intratumoral CD8\(^+\) T-cell infiltrate. Magnification, \(\times\) 100. H&E, hematoxylin and eosin.

Because our data generated using PTEN shRNA suggested that PTEN regulation of PD-L1 is transcriptional, we next investigated the effect of treatment with MK-2206 or...
Similarly, there was a significant decrease in CD4<sup>+</sup> and CD8<sup>+</sup> T cells isolated from healthy donor PBMCs cocultured with (i) MDA-MB-231 breast cancer cells transduced with a PTEN shRNA lentiviral vector, (ii) parental cells, or (iii) cells transduced with a control shRNA lentiviral vector. In experiments using PBMCs from three separate healthy donors, coculturing activated T cells with breast cancer cells with increased PD-L1 cell surface expression induced by PTEN-silencing resulted in a significant decrease in CD4<sup>+</sup> T-cell proliferation compared with PBMCs cocultured with parental cells (P < 0.0001; Fig. 5A). Similarly, there was a significant decrease in CD8<sup>+</sup> T-cell proliferation (P < 0.005; Fig. 5B). Similar results were seen using bulk PBMCs from MDA-MB-231 (Supplementary Fig. S2) and MDA-MB-157 cells (Supplementary Fig. S3). Annexin V assays showed increased apoptosis of both CD4<sup>+</sup> (Fig. 5C) and CD8<sup>+</sup> (Fig. 5D) T cells that were enriched from healthy donor PBMCs as well as CD4<sup>+</sup> and CD8<sup>+</sup> T cells in bulk PBMCs (Supplementary Fig. S4) cocultured with PTEN-silenced breast cancer cells. These data confirm a functional effect of PTEN loss that is mediated by increased PD-L1 expression.

**Discussion**

Evading antitumor immunity is a hallmark for the development and progression of cancer (25). Tumors use multiple mechanisms to avoid recognition by the host immune system, including expression of the negative T-cell regulatory molecule PD-L1 (11). In this study, we identified PD-L1 expression in approximately 20% of TNBC. We also showed that PTEN loss is one mechanism regulating PD-L1 at the transcriptional level and that this effect occurs via signaling through the PI3K pathway. Importantly, increased PD-L1 expression on the surface of TNBC cells had functional consequences on T cells including decreasing their proliferation and increasing apoptosis. These observations provide the rationale for implementing therapeutic strategies targeting the PD-1/PD-L1 axis in TNBC and suggest a role for enhanced antitumor immunity when targeting the PI3K pathway in TNBC.

PD-L1 is not expressed on normal epithelial tissues but is expressed on many cancers including renal cell carcinoma (20, 26), pancreatic cancer (27), ovarian cancer (28), gastric cancer (29), esophageal cancer (30), and hepatocellular carcinoma (31). PD-L1 expression in breast cancer has previously been investigated by Ghebeh and colleagues who identified PD-L1 expression in 22 (50%) of 44 tumors evaluated; in 15 (34%) it was restricted to the tumor epithelium, whereas in 18 (41%) it was identified in TILs (12). Furthermore, they found that intratumoral expression of PD-L1 was associated with high histologic grade and negative hormone receptor status. Consistent with the previous study, we found that approximately 20% of TNBC tumors express PD-L1. The majority (95%) of these TNBC tumors were grade 3.

The difference in the rates of PD-L1 expression in the current study (20%) and the study by Ghebeh and colleagues (34%) may be attributable to several factors. One important difference is that in our study, PD-L1 expression was assessed on TMAs. Importantly, this allowed us to evaluate a greater number of tumors. However, there are limitations of using a TMA. One limitation that is relevant for the current study is that multiple cores were dislodged during the PTEN and CD8 staining; however, there were limitations of using a TMA. One limitation that is relevant for the current study is that multiple cores were dislodged during the PTEN and CD8 staining; therefore, we only had PTEN data available for 17 of 20 PD-L1<sup>+</sup> tumors and CD8<sup>+</sup> T-cell data on 82 specimens. A second limitation of using a TMA is the small size (1 mm) of cores used to construct the TMA. However, because of the small size, and because tumor tissues are known to be heterogeneous, the rate of PD-L1 positivity identified in our study may be an underestimation of the true frequency of PD-L1 expression. Nonetheless, by showing PD-L1 expression in 20% of TNBC, we have provided a rationale for investigating PD-L1/PD-1 targeting therapies in TNBC, which is known to have few therapeutic options. The recently reported phase I study evaluating the anti-PD-1 antibody BMS-936588 included data from a nonrandom subset of patients enrolled on the trial in whom a
pretreatment biopsy was available to assess PD-L1 expression (14). Although this analysis included pretreatment biopsies from only 42 of 296 patients, investigators did make the observation that an objective response occurred in 9 (36%) of 25 patients with PD-L1–positive tumors. In contrast, none of the 17 patients with PD-L1–negative tumors responded. The investigators urge caution in interpreting these data due to the small sample size; nevertheless, their findings suggest that PD-L1 expression in pretreatment tumor samples predicts a greater likelihood of objective response. Future trials should incorporate biopsies to further test this hypothesis.

An interesting finding in our study was that in the 82 patients with TNBC in whom staining was available, there was a significantly greater number of intratumoral CD8+ T cells in tumors that were PD-L1+ when compared with PD-L1− tumors. This is in contrast to a recent study of 45 oral squamous cell carcinoma cases in which 39 cases had PD-L1 expression, which was associated with low peritumoral CD8+ T cell infiltrate (32). Our results, however, are consistent with a recent report from Taube and colleagues, who identified a strong association between the expression of PD-L1 in melanoma and TILs (33). In that study, 98% of PD-L1+ tumors

---

**Figure 3.** PTEN downregulation increases PD-L1 cell surface expression. MDA-MB-157, MCF7, and MDA-MB-231 breast cancer cell lines were transduced with PTEN shRNA lentiviral transduction particles. A–C, Western blot analysis performed on lysates obtained from these cells confirmed decreased PTEN expression. Nontargeting lentiviral transduction particles were used as a control. Actin was used to show equal loading. D–F, cell surface PD-L1 expression was evaluated by flow cytometry staining and PD-L1 MFI (mean ± SD) demonstrated a significant increase in PD-L1 expression on cells, correlating with a decrease in PTEN expression. Decreased PTEN expression in MDA-MB-231 cell line, which has the highest baseline cell surface expression of PD-L1, resulted in a significant further increase in PD-L1 expression. G–I, RNA was extracted from MDA-MB-157, MCF7, and MDA-MB-231 cells that were transduced with PTEN or nontargeting shRNA. Mean ± SD relative quotient (RQ) values obtained from qRT-PCR demonstrated a significant increase in the PD-L1 transcript that coincided with decreased PTEN expression. All assays were performed in triplicate. ANOVA test was performed using Prism 5.0 software (*, P < 0.05; **, P < 0.0001). MFI, median fluorescence intensity.
had associated TIL versus 28% of PD-L1+ tumors. Furthermore, IFN-γ expression was detected at the interface of PD-L1+ positive tumor cells and CD45-positive infiltrating immune cells. The results are also consistent with a study from Spranger and colleagues that showed CD8+ T cells in metastatic melanoma foci that also contained high levels of regulatory T cells and expressed the immunosuppressive factors indoleamine-2,3-dioxygenase (IDO) and PD-L1 (34). Mouse models from that study further suggested that PD-L1 upregulation was dependent on IFN-γ (34). Other studies evaluating PD-L1 regulation on antigen-presenting cells have shown that interleukin (IL)-6, IL-10, and the common γ-chain cytokines IL-2, IL-7, and IL-15 upregulate PD-L1 expression on tumor cells, suggesting that multiple factors present in the tumor microenvironment in addition to IFN-γ may promote increased PD-L1 expression by tumors (35, 36). These data suggest a positive feedback loop whereby inflammatory factors produced by immune cells in the tumor microenvironment cause tumor cells to increase cell surface expression of PD-L1 (37), a possible mechanism whereby tumor cells evade the adaptive immune response.

A second mechanism by which tumors can drive PD-L1 expression is by oncogenic signaling pathways. This was first demonstrated in glioblastomas when Parsa and colleagues showed that PTEN loss was associated with increased PD-L1 expression, suggesting the involvement of the PI3K pathway (15). Because PTEN loss is commonly seen in TNBC, we investigated the relationship between PTEN and PD-L1 expression. In approximately 50% of TNBC tumors included in our TMA in which there was >5% PD-L1 expression, we identified a loss of PTEN staining. Similarly, in a panel of TNBC cell lines, we found that two cell lines with PTEN loss, MDA-MB-468 and BT-549, had high cell surface PD-L1 expression. Together, these data suggest that there are likely multiple mechanisms of PD-L1 regulation in TNBC.

Using PTEN shRNA transduction particles, we generated stable cell lines and consistently found significantly increased PD-L1 expression after PTEN silencing. In addition, in the MDA-MB-468 cell line, which has PTEN loss and increased PI3K signaling, treatment with the AKT inhibitor MK-2206 and the mTOR inhibitor rapamycin resulted in decreased cell surface PD-L1 expression, confirming a role for PTEN loss and

---

**Figure 4.** Inhibition of the PI3K pathway decreases PD-L1 expression. A, MDA-MB-468 breast cancer cells were treated for 48 hours with the AKT inhibitor MK-2206 (500 nmol/L) after which PD-L1 cell surface expression assessed by flow cytometry. B, MDA-MB-468 breast cancer cells were treated with the mTOR inhibitor rapamycin (100 nmol/L). After 72 hours, cells were harvested and PD-L1 cell surface expression was assessed by flow cytometry. The addition of the PI3K pathway inhibitors significantly decreased the levels of surface PD-L1 expression. Data represent PD-L1 MFI (mean ± SD). Western blot analysis showing decreased expression of p-S6 confirmed pathway inhibition by MK-2206 and rapamycin. C, RNA was extracted from additional MDA-MB-468 breast cancer cells treated with MK-2206 or rapamycin. qRT-PCR showed a decrease in PD-L1 mRNA expression after addition of AKT and mTOR inhibitors. Data shown are representative of three separate experiments. All experiments were performed in triplicate. Data represent relative quotient (RQ) value (mean ± SD). ANOVA test was performed using Prism 5.0 software (*, P < 0.01). MFI, median fluorescence intensity.
PI3K signaling in PD-L1 regulation. Our results confirm findings from Crane and colleagues, who reported increased PD-L1 protein using Western blot analyses of whole-cell lysates in two PTEN-mutant breast cancer cell lines when compared with two PTEN wild-type cell lines (38). Furthermore, their data demonstrated decreased PD-L1 in the BT549 cell line following treatment with multiple inhibitors of the PI3K pathway. However, in contrast to the findings by Crane and colleagues showing regulation of PD-L1 by PTEN/PI3K signaling at the translational level, our data suggest transcriptional regulation of PD-L1 by PTEN/PI3K pathway. This discrepancy in our data and the previous report, along with our data showing high PD-L1 expression in two TNBC cell lines (MDA-MB-231 and HS-578T) with wild-type PTEN, highlight that multiple mechanisms may be involved in PD-L1 regulation in tumors. These mechanisms may be influenced by the tumor type and other oncogenic signaling pathways that are activated by the tumor cell. Ongoing work in our laboratory is investigating the mechanisms by which PTEN loss and increased PI3K signaling regulate PD-L1 expression.

In conclusion, we have shown that approximately 20% of cases of TNBC express PD-L1, suggesting a potential role for anti-PD-L1/anti-PD1 therapy in this patient population. Furthermore, we show that PTEN loss upregulates PD-L1 expression, indicating that therapeutic strategies targeting the PI3K pathway may enhance adaptive immune responses against
TNBC. Additional investigations are required to fully elucidate the mechanisms regulating PD-L1 expression in TNBC and to determine the extent of regulation by PTEN/PI3K pathway.

Disclosure of Potential Conflicts of Interest
M. Curran is a consultant/advisory board member of Jouve Therapeutics and Innocent. J.K. Litton has received commercial research support from Bristol-Myers Squibb and Chugai. No potential conflicts of interest were disclosed by the other authors.

Authors’ Contributions
Conception and design: E.A. Mittendorf, F. Meric-Bernstam, J.K. Litton, J.J. Molldrem, G. Alatrash
Development of methodology: E.A. Mittendorf, A.V. Philips, N. Qiao, M. Curran
Acquisition of data (provided animals, acquired and managed patients, provided facilities, etc.): A.V. Philips, N. Qiao, Y. Wu, S. Harrington, Y. Wang, A.M. Gonzalez-Angulo, A. Akcakanat, A. Chawla
Analysis and interpretation of data (e.g., statistical analysis, biostatistics, computational analysis): E.A. Mittendorf, A.V. Philips, N. Qiao, Y. Wu, X. Su, A.M. Gonzalez-Angulo, G. Alatrash
Writing, review, and/or revision of the manuscript: E.A. Mittendorf, F. Meric-Bernstam, Y. Wu, S. Harrington, A.M. Gonzalez-Angulo, M. Curran, P. Hwu, P. Sharma, J.K. Litton, G. Alatrash

References

Grant Support
This work was supported in part by grant R00CA133244 (to E.A. Mittendorf) and The State of Texas for Grant for Rare and Aggressive Cancer through the Morgan Welch Inflammatory Breast Cancer Research Program (to E.A. Mittendorf). F. Meric-Bernstam, A. Akcakanat, and A.M. Gonzalez-Angulo were supported by a Stand Up To Cancer Dream Team Translational Cancer Research Grant, a Program of the Entertainment Industry Foundation Foundation (SU2C-AACR-DT0209). This work was also supported by Susan G. Komen for the Cure SAC10006 (to F. Meric-Bernstam), National Center for Research Resources Grant 3UL1RR024148 (to F. Meric-Bernstam, X. Su, and Y. Wu), and NIH grant T32CA000999 (A. Chawla). The Flow Cytometry and Cellular Imaging core and Characterized Cell Line core are supported by Cancer Center Support Grant NCI P30CA16672.

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Received August 19, 2013; revised December 6, 2013; accepted December 31, 2013; published OnlineFirst January 10, 2014.


